mitomycin C


OTHER NAMES:
Mutamycint


DESCRIPTION: The mitomycins are a family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae. One of these compounds, mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour antibiotic activity. It is given intravenously to treat upper gastro-intestinal (e.g. esophageal carcinoma), anal cancers, and breast cancers, as well as by bladder instillation for superficial bladder tumours. It causes delayed bone marrow toxicity and therefore it is usually administered at 6-weekly intervals. Prolonged use may result in permanent bone-marrow damage. It may also cause lung fibrosis and renal damage.
Mitomycin C is a potent DNA crosslinker. A single crosslink per genome has shown to be effective in killing bacteria. This is accomplished by reductive activation followed by two N-alkylations. Both alkylations are sequence specific for a guanine nucleoside in the sequence 5'-CpG-3'. Potential bis-alkylating heterocylic quinones were synthetised in order to explore their antitumoral activities by bioreductive alkylation.

Mutamycin® - the anticancer drug that specifically targets DNA; used as a chemoterapeutic; alkylating agent forms interstrand and/or intrastrand crosslinks.

DNA DAMAGES:
intErstrand crosslinks (ICLs)
intrAstrand crosslink


Filter

Click on a column header name to sort

NAME STRUCTURE PROTEINS DNA DAMAGE EFFECT(S) PATHWAY(S) RELATED
intErstrand crosslinks (ICLs) UvrC
UvrB
ERCC5 (XPG)
ERCC4 (XPF)
MUS81
EME1
ERCC1
SLX4
SLX1A
SLX1B
TOP3A
cell cycle arrest
DNA backbone distortion
mutagenesis
stalled replication fork
Fanconi anemia (FA) pathway
nucleotide excision repair (NER)
prokaryotic (SOS) response
homologous recombination (HR)
DNA replication
intrAstrand crosslink UvrC
UvrB
ERCC5 (XPG)
ERCC4 (XPF)
cell cycle arrest
DNA backbone distortion
stalled replication fork
Fanconi anemia (FA) pathway
nucleotide excision repair (NER)
prokaryotic (SOS) response

Last modification date: Oct. 12, 2011